Key result
Elevated fasting plasma TMAO levels were independently associated with a higher SYNTAX score and diffuse coronary lesions.
Why the study?
Trimethylamine N-oxide (TMAO) has mechanistic links to atherosclerotic CAD pathogenesis and adverse outcomes, prompting examination of its relationship with CAD complexity, atherosclerotic burden, and the degree of subclinical myonecrosis.
Are elevated fasting plasma TMAO levels independently associated with greater coronary atherosclerotic burden and lesion complexity (SYNTAX score, SYNTAX score II, and diffuse lesions) and subclinical myonecrosis in stable patients with CAD?
Cohort (n=353)
Blinded outcome assessment (interventional cardiologist reviewing angiograms was blinded to TMAO level and clinical variable data)
No
Are elevated fasting plasma TMAO levels independently associated with greater coronary atherosclerotic burden and lesion complexity (SYNTAX score, SYNTAX score II, and diffuse lesions) and subclinical myonecrosis in stable patients with CAD?
Answers are grounded in this paper and cite their sources.
Fasting plasma TMAO is strongly and independently associated with higher angiographic coronary atherosclerotic burden (SYNTAX and SYNTAX II scores) and diffuse lesion morphology in stable CAD patients, supporting a link between gut microbe-dependent TMAO generation and coronary atherosclerosis severity.
BACKGROUND Trimethylamine N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, has mechanistic links to atherosclerotic coronary artery disease (CAD) pathogenesis and is associated with adverse outcomes. OBJECTIVES We examined the relationship between plasma TMAO levels and the complexity and burden of CAD and degree of subclinical myonecrosis. METHODS We studied 353 consecutive stable patients with evidence of atherosclerotic CAD detected on elective coronary angiography between 2012 and 2014 who had high-sensitivity cardiac troponin T (hs-cTnT) measured. SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores and lesion characteristics were used to quantify atherosclerotic burden. Fasting plasma TMAO was measured by mass spectrometry. RESULTS In this prospective cohort study, median TMAO level was 5.5 μM (interquartile range [IQR]: 3.4 to 9.8 μM); median SYNTAX score was 11.0 (IQR: 4.0 to 18.5); and 289 (81.9%), 40 (11.3%) and 24 (6.8%) patients had low (0 to 22), intermediate (23 to 32), and high (≥33) SYNTAX scores, respectively. Plasma TMAO levels correlated (all p < 0.0001) with SYNTAX score (r = 0.61), SYNTAX score II (r = 0.62), and hs-cTnT (r = 0.29). Adjusting for traditional risk factors, body mass index, medications, lesion characteristic, renal function, and high-sensitivity C-reactive protein, elevated TMAO levels remained independently associated with a higher SYNTAX score (odds ratio [OR]: 4.82; p < 0.0001), SYNTAX score II (OR: 1.88; p = 0.0002) but not with subclinical myonecrosis (OR: 1.14; p = 0.3147). Elevated TMAO level was an independent predictor of the presence of diffuse lesions, even following adjustments for traditional risk factors and hs-cTnT (OR: 2.05; 95% confidence interval: 1.45 to 2.9; p = 0.0001). CONCLUSIONS Fasting plasma TMAO levels are an independent predictor for high atherosclerotic burden in patients with CAD.
No takes yet. Share an insight, caveat, or question.
Senthong et al. (2016) conducted a cohort in Stable atherosclerotic coronary artery disease (CAD) (n=353). Elevated fasting plasma trimethylamine N-oxide (TMAO) levels vs. Lower plasma TMAO levels was evaluated on Higher atherosclerotic burden quantified by higher SYNTAX score tertile (fully adjusted model) (OR 4.82, p=<0.0001). Elevated fasting plasma TMAO levels were independently associated with a higher SYNTAX score and diffuse coronary lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: